Oxycodone Hcl/Acetaminophen
Brand names: Endocet, Oxycodone-Acetaminophen, Percocet, Nalocet, Prolate
Part of: Opioid painkillers
At a glance
- Medicare prescriptions, 2024
- 8,061,310
- Medicare drug cost
- $273.2M
- Average cost per prescription
- $33.89
- Clinicians who prescribed it
- 112,048
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Oxycodone Hydrochloride Capsules are an opioid agonist indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, overdose, and death, which can occur at any dosage or duration, and persist over the course of therapy, reserve opioid analgesics, including Oxycodone Hydrochloride Capsules, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
From the FDA-approved prescribing information (label dated September 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HYDROCHLORIDE CAPSULES Addiction, Abuse, and Misuse Because the use of Oxycodone Hydrochloride Capsules exposes patients and other users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of Oxycodone Hydrochloride Capsules, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Oxycodone Hydrochloride Capsules are essential. Accidental Ingestion Accidental ingestion of even one dose of Oxycodone Hydrochloride Capsules, especially by children, can…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Pain Medicine 20.8%
- Nurse Practitioners 17.9%
- Family Medicine 15.3%
- Physician Assistants 11.6%
- Internal Medicine 10.4%
- Orthopedic Surgery 3.8%
- Physical Medicine & Rehabilitation (PM&R) 3.8%
- Anesthesiology 2.1%
- Emergency Medicine 1.6%
- General Surgery 1.2%
- Sports Medicine 0.9%
- Urology 0.8%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 2% from 2019 to 2024.
Biggest change by state since 2019
- Texas +24%
- Alabama +23%
- Mississippi +21%
- Indiana +17%
- Idaho +15%
- Puerto Rico (smallest change) −36%
- Hawaii (smallest change) −26%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Kvk-Tech, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | brown capsule, 14 mm | K 23 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $120,601 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Forte Bio-pharma LLC $120,601
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.